Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

Novartis and Pfizer to collaborate on NASH combinations

Novo Nordisk and Bristol-Myers Squibb are also all active in the field, while AstraZeneca has been busy this year signing new collaborations with the likes of Ionis.

Latest news

Alnylam gets EU nod for Onpattro amid pricing backlash

Ionis and Akcea secured EMA approval last month for their antisense candidate Tegsedi (inotersen), but are still in the process of negotiating price and reimbursement with individual EU countries, while ... Neither Tegsedi or Vyndaqel are approved yet in
ICER says Alnylam’s Onpattro should cost 90%-95% less

In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’antisense candidate Tegsedi (inotersen) which is due for an FDA
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding. ... The news sent Akcea’s share price crashing, and spoils the recent good news of Ionis’first ever drug approval, Tegsedi, gaining clearance from the EU in July.
Alnylam claims first RNAi approval from FDA for patisiran

Patisiran is the first FDA-approved drug for hATTR amyloidosis in the US, but will only claim third place in Europe after Akcea/Ionis’antisense oligonucleotide rival Tegsedi (inotersen), which was
Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

The announcement adds to the momentum behind Ionis, which has just gained its first ever drug approval - also in Europe. ... C. Frank Bennett, senior vice president of research and franchise leader for the neurological programmes at Ionis.

More from news
Approximately 10 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐ targeted therapeutics for complement mediated. ... Roche. RNA‐ targeted therapeutic, IONIS‐ FB‐ LRx targeting Factor. B, for Geographic Atrophy, an advanced form
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

While Onpattro has outshone Ionis’product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration
Deal Watch January 2017

As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Antisense Oligonucleotides Market Intelligence and Analysis for Period (2017-2027)

Antisense Oligonucleotides Market: Key Players. Some of the players identified in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Production Manager – Healthcare Communications: DOE

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Senior Medical Writer: Competitive Salary

Events Manager – Med Comms – Surrey: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Medical Writers Required – Cheshire: DOE

Associate Director, Market Access & HEOR – North-West: Negotiable

Senior Account Executive, London, Medical Communications: Excellent package

Account Director: £48, 000 - £60, 000

Associate Medical Director: Excellent PTO, bonus and 401k package

Account Director: Excellent benefits

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

New Business Director - PR: Competitive Salary and benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Healthcare Communications Account Directors x 2: Salary TBC

Principal Health Economist - North-West: Negotiable

Senior Medical Writer (Remote Working): Competitive Salary Offered

Medical/ Scientific Director: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Client Services Director – Medical Education Agency – North West...: Salary TBC

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...